Compare · CCEL vs OTRK
CCEL vs OTRK
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Ontrak Inc. (OTRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and OTRK operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- CCEL is the larger of the two at $83.3M, about 1.5x OTRK ($56.3M).
- Over the past year, CCEL is down 36.1% and OTRK is down 78.9% - CCEL leads by 42.7 points.
- CCEL has hit the wire 1 time in the past 4 weeks while OTRK has been quiet.
- OTRK has more recent analyst coverage (5 ratings vs 0 for CCEL).
- Company
- Cryo-Cell International Inc.
- Ontrak Inc.
- Price
- $3.41-1.16%
- $0.32-13.05%
- Market cap
- $83.3M
- $56.3M
- 1M return
- -3.67%
- +2.94%
- 1Y return
- -36.14%
- -78.87%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 1
- 0
- Recent ratings
- 0
- 5
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Ontrak Inc.
Ontrak, Inc. operates as an artificial intelligence powered, virtualized outpatient healthcare treatment company that provides in-person or telehealth intervention services to health plans and other third-party payors. Its Ontrak PRE (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends care pathways that people are willing to follow, and engages people who aren't getting the care they need. The company's technology-enabled, OnTrak, program is designed to treat health plan members with unaddressed behavioral health conditions that cause or exacerbate chronic medical diseases, such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was founded in 2003 and is headquartered in Santa Monica, California.
Latest CCEL
- VP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
- Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives NYSE American Continued Listing Notice
- SEC Form 10-K filed by Cryo-Cell International Inc.
- Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
Latest OTRK
- Ontrak Inc. filed SEC Form 8-K: Other Events, Leadership Update
- SEC Form NT 10-Q filed by Ontrak Inc.
- Ontrak Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Ontrak Inc. filed SEC Form 8-K: Other Events, Leadership Update
- Electronic Data Interchange Market Size to Grow USD 74.36 billion by 2031, Rising Digital Transformation Across Various Industries Propels | The Insight Partners
- Ontrak Inc. filed SEC Form 8-K: Other Events
- Ontrak Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Ontrak Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 424B5 filed by Ontrak Inc.
- Ontrak Health Announces Pricing of $4 Million Public Offering